Imunopharm Technology Co., Ltd., a Chinese biotech specializing in gene and cell therapies, has filed for an IPO on the Shanghai Stock Exchange's STAR Market to raise 2.5 billion yuan ($345 million). The funds will support R&D, manufacturing, and working capital. Founded in 2015 by a Tsinghua University team, the company has developed core platforms for gene delivery and immune cell therapies. Its flagship product, IM19, a CD19-targeting CAR-T therapy for non-Hodgkin lymphoma, has submitted an NDA and secured commercialization rights with Huadong Medicine. The pipeline extends to solid tumors with IM96 (globally approved for colorectal cancer trials), autoimmune diseases with ZM001, and next-gen technologies like in vivo CAR-T. Despite operating at a loss, the company aims to leverage its innovative platforms and diverse pipeline to compete in China's growing CAR-T market.

BeOne Medicines announced that its Phase 3 MANGROVE trial met its primary endpoint, demonstrating that a chemotherapy-free regimen of zanubrutinib plus rituximab significantly reduced the risk of disease progression or death by 43% compared to standard bendamustine-rituximab in previously untreated mantle cell lymphoma patients (HR=0.57). This marks the first Phase 3 trial evaluating a chemotherapy-free, BTK inhibitor-based regimen in the first-line setting, offering a highly effective alternative that spares patients, particularly the elderly, from the cumulative toxicities and infusion burden of traditional chemotherapy. The company plans to present full results at an upcoming medical conference and expects to file for regulatory approvals in the second half of 2026.

In June 2026, Yescarta® (axicabtagene ciloleucel), the flagship CAR-T therapy from Shanghai Fosun Kairos Biotechnology, celebrates its fifth anniversary as China's first approved cell therapy product. Approved by the NMPA on June 22, 2021, Yescarta® broke the zero-to-one barrier in domestic cell treatment and has since treated over 1,500 patients with relapsed or refractory lymphoma. Key milestones include China's first CAR-T patient achieving over eight years of cancer-free survival, the approval of a second indication for adult large B-cell lymphoma in June 2023, and the establishment of a national treatment network spanning more than 200 high-standard treatment centers across 29 provinces. The company's third indication filing for indolent non-Hodgkin lymphoma has received Breakthrough Therapy Designation. Looking forward, Fosun Kairos plans to expand its pipeline into solid tumors, autoimmune diseases, and frontier technologies including in-vivo CAR-T and CAR-NK therapies, solidifying its position as a leader in China's cell and gene therapy field.